Cargando…

Current Status of 5α-Reductase Inhibitors in Prostate Disease Management

The key enzyme in the androgen synthesis and androgen receptor pathways is 5α-reductase (5-AR), which occurs as three isoenzymes. Types I and II 5-ARs the most important clinically, and two different 5-AR inhibitors (5-ARIs), finasteride and dutasteride, have been developed. Several urology associat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Dong Il, Chung, Jae Il
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630338/ https://www.ncbi.nlm.nih.gov/pubmed/23614056 http://dx.doi.org/10.4111/kju.2013.54.4.213

Ejemplares similares

Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH
por: Gravas, Stavros, et al.
Publicado: (2009)

Role of 5 alpha-reductase inhibitors in the management of prostate cancer
por: Hudak, Steven J, et al.
Publicado: (2006)

5-alpha reductase inhibitors use in prostatic disease and beyond
por: Chislett, Bodie, et al.
Publicado: (2023)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
por: Busato, Wilson F. S.
Publicado: (2020)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea
por: An, Min Ho, et al.
Publicado: (2023)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer
por: Bhattacharjee, Biplab, et al.
Publicado: (2011)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer
por: Fiandalo, Michael V., et al.
Publicado: (2019)

Current status of biosimilars in the treatment of inflammatory bowel diseases
por: Park, Dong Il
Publicado: (2016)

The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
por: Traish, Abdulmaged M., et al.
Publicado: (2014)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
por: Kumar, Abhishek, et al.
Publicado: (2019)

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy
por: Heo, Ji Eun, et al.
Publicado: (2018)

Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle
por: Tampucci, Silvia, et al.
Publicado: (2022)

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors
por: Foldes, Cara A., et al.
Publicado: (2020)

The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging
por: Kim, Jung Kwon, et al.
Publicado: (2019)

5α-reductase inhibitors impact prognosis of urothelial carcinoma
por: Wang, Chien-Sheng, et al.
Publicado: (2020)

Is There a Link between 5α-Reductase Inhibitors and Hypoglycemia?
por: Jeong, Jin Woo, et al.
Publicado: (2021)

Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014)

5-alpha-reductase and the development of the human prostate
por: Radmayr, C., et al.
Publicado: (2008)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2017)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
por: Wang, Ziting, et al.
Publicado: (2023)

Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models
por: Poirier, Andrée-Anne, et al.
Publicado: (2022)

Androgen Regulation of 5α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention
por: Li, Jin, et al.
Publicado: (2011)

Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications
por: Wang, Kai, et al.
Publicado: (2014)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Preoperative treatment with 5α-reductase inhibitors and the risk of hemorrhagic events in patients undergoing transurethral resection of the prostate – A population-based cohort study
por: Yang, Ti-Yuan, et al.
Publicado: (2018)

Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase
por: Youn, Dong-Hyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sos0rlbad08l3k3np6fshqq1av